JP2012522053A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012522053A5 JP2012522053A5 JP2012503512A JP2012503512A JP2012522053A5 JP 2012522053 A5 JP2012522053 A5 JP 2012522053A5 JP 2012503512 A JP2012503512 A JP 2012503512A JP 2012503512 A JP2012503512 A JP 2012503512A JP 2012522053 A5 JP2012522053 A5 JP 2012522053A5
- Authority
- JP
- Japan
- Prior art keywords
- imidazol
- phenyl
- pyrrolidinyl
- methyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 carboxy, formyl Chemical group 0.000 claims 89
- 229910052739 hydrogen Inorganic materials 0.000 claims 56
- 239000001257 hydrogen Substances 0.000 claims 56
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 46
- 125000000217 alkyl group Chemical group 0.000 claims 45
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 36
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 33
- 150000002431 hydrogen Chemical group 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 26
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 25
- 125000003118 aryl group Chemical group 0.000 claims 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims 21
- 125000003710 aryl alkyl group Chemical group 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 7
- 239000004202 carbamide Substances 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Chemical group 0.000 claims 4
- 229910052717 sulfur Chemical group 0.000 claims 4
- 239000011593 sulfur Chemical group 0.000 claims 4
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000005469 ethylenyl group Chemical group 0.000 claims 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000002348 inosinate dehydrogenase inhibitor Substances 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 229960000329 ribavirin Drugs 0.000 claims 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 2
- 229960000888 rimantadine Drugs 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- ZBGKKYUXZMMPHM-JPYDVTDNSA-N (2r)-2-hydroxy-1-[(2s)-2-[5-[4-[2-[4-[2-[(2s)-1-[(2r)-2-hydroxy-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]ethyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](O)C(=O)N2CCC[C@H]2C=2NC=C(N=2)C2=CC=C(C=C2)CCC2=CC=C(C=C2)C=2N=C(NC=2)[C@@H]2CCCN2C(=O)[C@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZBGKKYUXZMMPHM-JPYDVTDNSA-N 0.000 claims 1
- YLKPEGAEKOBUPL-JPYDVTDNSA-N (2r)-2-hydroxy-1-[(2s)-2-[5-[4-[[3-[2-[(2s)-1-[(2r)-2-hydroxy-2-phenylacetyl]pyrrolidin-2-yl]-1h-imidazol-5-yl]phenyl]methoxymethyl]phenyl]-1h-imidazol-2-yl]pyrrolidin-1-yl]-2-phenylethanone Chemical compound C1([C@@H](O)C(=O)N2CCC[C@H]2C=2NC=C(N=2)C=2C=CC=C(C=2)COCC2=CC=C(C=C2)C=2N=C(NC=2)[C@@H]2CCCN2C(=O)[C@H](O)C=2C=CC=CC=2)=CC=CC=C1 YLKPEGAEKOBUPL-JPYDVTDNSA-N 0.000 claims 1
- URBNHSPLMPSGPV-IYTFMMMVSA-N 1-ethyl-3-[(1R)-2-[(2S)-2-[5-[4-[2-[4-[2-[(2S)-1-[(2R)-2-(ethylcarbamoylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]ethyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]urea Chemical compound C1([C@@H](NC(=O)NCC)C(=O)N2CCC[C@H]2C=2NC=C(N=2)C2=CC=C(C=C2)CCC2=CC=C(C=C2)C=2N=C(NC=2)[C@@H]2CCCN2C(=O)[C@H](NC(=O)NCC)C=2C=CC=CC=2)=CC=CC=C1 URBNHSPLMPSGPV-IYTFMMMVSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000006501 nitrophenyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16453109P | 2009-03-30 | 2009-03-30 | |
| US61/164,531 | 2009-03-30 | ||
| US12/729,940 | 2010-03-23 | ||
| US12/729,940 US8796466B2 (en) | 2009-03-30 | 2010-03-23 | Hepatitis C virus inhibitors |
| PCT/US2010/028456 WO2010117635A1 (en) | 2009-03-30 | 2010-03-24 | Hepatitis c virus inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012522053A JP2012522053A (ja) | 2012-09-20 |
| JP2012522053A5 true JP2012522053A5 (enExample) | 2013-04-25 |
| JP5612660B2 JP5612660B2 (ja) | 2014-10-22 |
Family
ID=42320079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012503512A Expired - Fee Related JP5612660B2 (ja) | 2009-03-30 | 2010-03-24 | Ｃ型肝炎ウイルス阻害剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8796466B2 (enExample) |
| EP (1) | EP2414350B1 (enExample) |
| JP (1) | JP5612660B2 (enExample) |
| KR (1) | KR20120034603A (enExample) |
| CN (1) | CN102448956B (enExample) |
| AR (1) | AR076002A1 (enExample) |
| AU (1) | AU2010234970A1 (enExample) |
| BR (1) | BRPI1013393A2 (enExample) |
| CA (1) | CA2757269A1 (enExample) |
| CL (1) | CL2011002426A1 (enExample) |
| CO (1) | CO6430431A2 (enExample) |
| EA (1) | EA022384B1 (enExample) |
| IL (1) | IL215055A0 (enExample) |
| MX (1) | MX2011009948A (enExample) |
| NZ (1) | NZ595168A (enExample) |
| PE (1) | PE20120546A1 (enExample) |
| SG (1) | SG174521A1 (enExample) |
| WO (1) | WO2010117635A1 (enExample) |
| ZA (1) | ZA201106795B (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA024853B1 (ru) | 2008-12-03 | 2016-10-31 | Пресидио Фармасьютикалс, Инк. | Ингибиторы ns5a вгс |
| RU2505540C2 (ru) | 2008-12-23 | 2014-01-27 | Эббви Инк. | Антивирусные соединения |
| US8546405B2 (en) | 2008-12-23 | 2013-10-01 | Abbott Laboratories | Anti-viral compounds |
| US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2758484A1 (en) * | 2009-04-15 | 2010-10-21 | David A. Degoey | Anti-viral compounds |
| JP2012524761A (ja) * | 2009-04-24 | 2012-10-18 | テイボテク・フアーマシユーチカルズ | ジアリールエーテル類 |
| ES2758726T3 (es) | 2009-05-13 | 2020-05-06 | Gilead Pharmasset Llc | Compuestos antivirales |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PL2628481T3 (pl) * | 2009-06-11 | 2016-08-31 | Abbvie Bahamas Ltd | Tripodstawione heterocykle jako inhibitory replikacji wirusa HCV zapalenia wątroby typu C |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| AU2010274001A1 (en) | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
| SG178952A1 (en) | 2009-09-04 | 2012-04-27 | Glaxosmithkline Llc | Chemical compounds |
| US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011091417A1 (en) | 2010-01-25 | 2011-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| KR20120124495A (ko) | 2010-03-04 | 2012-11-13 | 이난타 파마슈티칼스, 인코포레이티드 | Ｈｃｖ 복제의 억제제로서의 조합 제약 작용제 |
| WO2011119853A1 (en) * | 2010-03-24 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| EP2555622A4 (en) | 2010-04-09 | 2013-09-18 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US20130296311A1 (en) * | 2010-05-28 | 2013-11-07 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| WO2012006070A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| AR081691A1 (es) | 2010-06-28 | 2012-10-10 | Vertex Pharma | Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus |
| EP2585448A1 (en) | 2010-06-28 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| WO2012021704A1 (en) | 2010-08-12 | 2012-02-16 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| CA2808291A1 (en) | 2010-08-17 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flaviviridae viral infections |
| JP5619289B2 (ja) * | 2010-09-24 | 2014-11-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| AU2014203655B2 (en) * | 2010-10-13 | 2016-07-07 | Abbvie Ireland Unlimited Company | Anti-viral compounds |
| RU2452735C1 (ru) | 2010-11-30 | 2012-06-10 | Александр Васильевич Иващенко | Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения |
| EP2651924A1 (en) * | 2010-12-16 | 2013-10-23 | Abbvie Inc. | Anti-viral compounds |
| MX2013006951A (es) * | 2010-12-16 | 2013-10-03 | Abbvie Inc | Compuestos antivirales. |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) * | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| EP2709455A4 (en) | 2011-05-18 | 2014-11-05 | Enanta Pharm Inc | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO [2.4] HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES |
| BR112014000563A2 (pt) * | 2011-07-09 | 2019-12-10 | Sunshine Lake Pharma Co., Ltd | composto, composição farmacêutica, e, uso do composto |
| WO2013016492A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Thiophene compounds |
| WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
| PH12014500312A1 (en) | 2011-08-08 | 2014-03-31 | Lupin Ltd | Imidazole derivatives as antiviral agents |
| DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
| AU2012332358B2 (en) | 2011-11-03 | 2017-07-13 | Theravance Biopharma R&D Ip, Llc | Rod -like hepatitis C virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1H - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine |
| AU2012360905B2 (en) | 2011-12-28 | 2017-04-27 | Janssen Sciences Ireland Uc | Hetero-bicyclic derivatives as HCV inhibitors |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| HK1203356A1 (en) | 2012-03-22 | 2015-10-30 | 艾丽奥斯生物制药有限公司 | Pharmaceutical combinations comprising a thionucleotide analog |
| LT2850075T (lt) | 2012-04-25 | 2017-05-10 | Theravance Biopharma R&D Ip, Llc | Piperazino-piperidino junginiai, kaip hepatito c viruso inhibitoriai |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| RU2507201C1 (ru) | 2013-02-07 | 2014-02-20 | Александр Васильевич Иващенко | Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
| US20150065439A1 (en) | 2013-02-28 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US9334291B2 (en) * | 2013-06-06 | 2016-05-10 | AB Pharma Ltd. | Antiviral compounds highly effective as HCV-NS5A inhibitor |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| CN104628584B (zh) * | 2013-11-08 | 2017-03-08 | 广州朗圣药业有限公司 | 一种适合工业化的高纯度达泊西汀的制备方法 |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN105294713A (zh) * | 2015-10-09 | 2016-02-03 | 重庆康施恩化工有限公司 | Velpatasvir中间体及其制备方法 |
| CN108349945B (zh) * | 2015-11-06 | 2021-10-29 | 江苏豪森药业集团有限公司 | Hcv抑制剂、其制备方法与应用 |
| CN108164486B (zh) * | 2018-03-06 | 2021-02-12 | 徐州医科大学 | 一种醚类化合物的绿色高效合成方法 |
| WO2020061146A1 (en) * | 2018-09-19 | 2020-03-26 | Dow Agrosciences Llc | Preparation of halogen analogs of picloram |
| CN109456375B (zh) * | 2018-12-11 | 2019-10-22 | 枣庄学院 | 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法 |
| JP7725617B2 (ja) | 2021-05-21 | 2025-08-19 | ギリアード サイエンシーズ， インコーポレイテッド | ジカウイルス阻害剤としての五環式誘導体 |
| WO2022246072A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654451B1 (en) | 1993-01-14 | 2000-02-22 | Magainin Pharma | Amino acids and peptides having modified c-terminals and modified n-terminals |
| EP0679153A4 (en) | 1993-01-14 | 1996-05-15 | Magainin Pharma | FINALLY MODIFIED AMINO ACIDS AND PEPTIDES. |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| WO2004005264A2 (en) | 2002-07-05 | 2004-01-15 | Axxima Pharmaceuticals Ag | Imidazole compounds for the treatment of hepatitis c virus infections |
| WO2004014852A2 (en) | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| WO2006093867A1 (en) | 2005-02-28 | 2006-09-08 | The Rockefeller University | Structure of the hepatitits c virus ns5a protein |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| ES2348332T3 (es) | 2005-09-16 | 2010-12-02 | Arrow Therapeutics Limited | Derivados de bifenilo y su uso en el tratamiento de la hepatitis c. |
| WO2007058384A1 (en) | 2005-11-17 | 2007-05-24 | Osaka University | Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same |
| NZ569817A (en) | 2005-12-21 | 2011-10-28 | Abbott Lab | Anti-viral compounds |
| EP1971611B1 (en) | 2005-12-21 | 2012-10-10 | Abbott Laboratories | Anti-viral compounds |
| SG133452A1 (en) | 2005-12-30 | 2007-07-30 | Novartis Ag | Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases |
| CA2653924A1 (en) | 2006-05-30 | 2007-12-06 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| US9873667B2 (en) | 2006-07-27 | 2018-01-23 | Emisphere Technologies Inc. | Arylsulfanyl compounds and compositions for delivering active agents |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100158862A1 (en) | 2006-08-11 | 2010-06-24 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| TW200831084A (en) | 2006-11-21 | 2008-08-01 | Genelabs Tech Inc | Anti-viral compounds |
| US8236950B2 (en) | 2006-12-20 | 2012-08-07 | Abbott Laboratories | Anti-viral compounds |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US8491023B2 (en) * | 2007-09-04 | 2013-07-23 | Schlage Lock Company Llc | Door lock assembly |
| CN101389072B (zh) * | 2007-09-12 | 2011-05-25 | 中兴通讯股份有限公司 | 高速下行共享信道的传输信道时间调整方法 |
| EP2250163B1 (en) | 2008-02-12 | 2012-03-28 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| BRPI0907733A2 (pt) | 2008-02-12 | 2015-07-14 | Bristol Myers Squibb Co | Inibidores do vírus da hepatite c |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2010008863A (es) | 2008-02-13 | 2010-09-07 | Bristol Myers Squibb Co | Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatisis c. |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8383094B2 (en) | 2008-10-01 | 2013-02-26 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8729077B2 (en) | 2008-11-28 | 2014-05-20 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| EA024853B1 (ru) | 2008-12-03 | 2016-10-31 | Пресидио Фармасьютикалс, Инк. | Ингибиторы ns5a вгс |
| KR20110098779A (ko) | 2008-12-03 | 2011-09-01 | 프레시디오 파마슈티칼스, 인코포레이티드 | Ｈｃｖ ｎｓ5ａ의 억제제 |
| RU2505540C2 (ru) | 2008-12-23 | 2014-01-27 | Эббви Инк. | Антивирусные соединения |
| EP2393359A4 (en) | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | COMPOUND DIBENZIMIDAZOLE DERIVATIVES |
| WO2010096462A1 (en) | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| US8420686B2 (en) * | 2009-02-17 | 2013-04-16 | Enanta Pharmaceuticals, Inc. | Linked diimidazole antivirals |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| CA2753313A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| UY32462A (es) | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
| RU2544010C2 (ru) | 2009-02-27 | 2015-03-10 | Энанта Фармасьютикалс, Инк. | Ингибиторы вируса гепатита с |
| KR20110131312A (ko) | 2009-03-27 | 2011-12-06 | 프레시디오 파마슈티칼스, 인코포레이티드 | 융합된 고리 ｃ형 간염 억제제 |
| MX2011010084A (es) | 2009-03-27 | 2011-10-14 | Merck Sharp & Dohme | Inhibidores de la replicacion del virus de la hepatitis c. |
| US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| TWI476190B (zh) | 2009-03-30 | 2015-03-11 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2758484A1 (en) | 2009-04-15 | 2010-10-21 | David A. Degoey | Anti-viral compounds |
| JP2012524761A (ja) | 2009-04-24 | 2012-10-18 | テイボテク・フアーマシユーチカルズ | ジアリールエーテル類 |
| CA2760205A1 (en) | 2009-05-12 | 2010-11-18 | Schering Corporation | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| ES2758726T3 (es) | 2009-05-13 | 2020-05-06 | Gilead Pharmasset Llc | Compuestos antivirales |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8772505B2 (en) | 2009-05-29 | 2014-07-08 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C |
| US8980920B2 (en) | 2009-05-29 | 2015-03-17 | Merck Sharp & Dohme Corp. | Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PL2628481T3 (pl) | 2009-06-11 | 2016-08-31 | Abbvie Bahamas Ltd | Tripodstawione heterocykle jako inhibitory replikacji wirusa HCV zapalenia wątroby typu C |
| WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| AU2010274001A1 (en) | 2009-07-16 | 2012-02-23 | Vertex Pharmaceuticals Incorporated | Benzimidazole analogues for the treatment or prevention of Flavivirus infections |
| WO2011015657A1 (en) | 2009-08-07 | 2011-02-10 | Tibotec Pharmaceuticals | Phenyl ethynyl derivatives as hepatitis c virus inhibitors |
| RU2540897C2 (ru) | 2009-08-07 | 2015-02-10 | Тиботек Фармасьютикалз | Производные бис-бензимидазола в качестве ингибиторов вируса гепатита с |
| RU2012112824A (ru) | 2009-09-03 | 2013-10-10 | Тиботек Фармасьютикалз | Производные бис-бензимидазола |
| SG178952A1 (en) | 2009-09-04 | 2012-04-27 | Glaxosmithkline Llc | Chemical compounds |
| WO2011031934A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| WO2011050146A1 (en) | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Chemical compounds |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2503881B1 (en) | 2009-11-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| US8415482B2 (en) | 2009-12-04 | 2013-04-09 | National Health Research Institutes | Proline derivatives |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN104530079B (zh) | 2009-12-18 | 2017-10-20 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| MX2012006877A (es) | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
| CA2785488A1 (en) | 2009-12-22 | 2011-07-21 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| CA2784036A1 (en) | 2009-12-24 | 2011-06-30 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| WO2011091417A1 (en) | 2010-01-25 | 2011-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2011091532A1 (en) | 2010-01-28 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
-
2010
- 2010-03-23 US US12/729,940 patent/US8796466B2/en active Active
- 2010-03-24 JP JP2012503512A patent/JP5612660B2/ja not_active Expired - Fee Related
- 2010-03-24 WO PCT/US2010/028456 patent/WO2010117635A1/en not_active Ceased
- 2010-03-24 PE PE2011001734A patent/PE20120546A1/es not_active Application Discontinuation
- 2010-03-24 CA CA2757269A patent/CA2757269A1/en not_active Abandoned
- 2010-03-24 EA EA201171152A patent/EA022384B1/ru not_active IP Right Cessation
- 2010-03-24 EP EP10722818.1A patent/EP2414350B1/en not_active Not-in-force
- 2010-03-24 BR BRPI1013393A patent/BRPI1013393A2/pt active Search and Examination
- 2010-03-24 AU AU2010234970A patent/AU2010234970A1/en not_active Abandoned
- 2010-03-24 SG SG2011068657A patent/SG174521A1/en unknown
- 2010-03-24 KR KR1020117025611A patent/KR20120034603A/ko not_active Ceased
- 2010-03-24 NZ NZ595168A patent/NZ595168A/xx not_active IP Right Cessation
- 2010-03-24 MX MX2011009948A patent/MX2011009948A/es active IP Right Grant
- 2010-03-24 CN CN201080024916.0A patent/CN102448956B/zh not_active Expired - Fee Related
- 2010-03-30 AR ARP100101038A patent/AR076002A1/es unknown
-
2011
- 2011-09-08 IL IL215055A patent/IL215055A0/en unknown
- 2011-09-16 ZA ZA2011/06795A patent/ZA201106795B/en unknown
- 2011-09-21 CO CO11123611A patent/CO6430431A2/es active IP Right Grant
- 2011-09-30 CL CL2011002426A patent/CL2011002426A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012522053A5 (enExample) | ||
| JP2012522056A5 (enExample) | ||
| JP2012523457A5 (enExample) | ||
| JP2013510857A5 (enExample) | ||
| JP2012528166A5 (enExample) | ||
| JP2014513690A5 (enExample) | ||
| JP2013510853A5 (enExample) | ||
| JP2012523415A5 (enExample) | ||
| JP2010500414A5 (enExample) | ||
| KR101492672B1 (ko) | Ｃ형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸 | |
| HRP20140737T1 (hr) | Inhibitori hepatitis c virusa | |
| JP2011530531A5 (enExample) | ||
| JP2012518000A5 (enExample) | ||
| JP2010510233A5 (enExample) | ||
| JP2010500415A5 (enExample) | ||
| RU2342383C2 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5 | |
| EA031030B1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| RU2011146059A (ru) | Конденсированное пирролопиридиновое производное | |
| JP2018502925A5 (enExample) | ||
| CA2682329A1 (en) | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | |
| RU2011153788A (ru) | Гетероциклические противовирусные соединения | |
| EA201000196A1 (ru) | Кристаллическая форма дигидрохлорида метил((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((метоксикарбонил)амино)-3-метилбутаноил)-2-пирролидинил)-1н-имидазол-5-ил)-4-бифенилил)-1н-имидазол-2-ил)-1-пирролидинил)карбонил)-2-метилпропил)карбамата | |
| RU2007128322A (ru) | Циклические производные пиррола | |
| JP2011511837A5 (enExample) | ||
| JP2012528161A5 (enExample) |